**Background:** Rapid diagnosis of MERS-CoV infection is essential for the successful clinical management and isolation of MERS patients. The prototype Idylla™ MERS assay is a RT-PCR based assay which generates highly sensitive, specific results with a minimal turn-around time. Two independent PCR assays, targeting different regions in the MERS-CoV genome, are combined to detect and at the same time confirm infection with MERS-CoV. The prototype Idylla™ MERS assay is a single-use cartridge that will be run in the fully automated Idylla™ MDx Platform. The cartridge contains all reagents and is capable of processing samples without any user manipulation, minimizing the possibility of errors in setup and decreasing the risk of infection or contamination. The aim of this work was to demonstrate the performance of the prototype Idylla™ MERS assay on the Idylla™ Platform.

**Methods:** Performance of the prototype Idylla™ MERS assay was assessed using serial dilutions of viral culture spiked in MERS-CoV negative clinical material. The performance of the prototype Idylla™ MERS assay was compared to a conventional RT-PCR kit in combination with extraction by the NucliSENS^®^ easyMag^®^. In vitro transcribed MERS-CoV RNA was used to determine the LoD of the assay and to show reproducibility. Cross-reactivity was analysed using culture and clinical specimen positive of other respiratory pathogens. Additionally, an *in-silico* analysis was performed to prove the reactivity with all available MERS-CoV sequences and to exclude any cross-reactivity with organisms present in respiratory specimen or with the human genome.

**Results:** The prototype Idylla™ MERS assay demonstrated high sensitivity and specificity. The analysis of MERS-CoV viral culture showed the same sensitivity with the Idylla™ MERS assay as a conventional MERS RT-PCR kit in combination with NucliSENS^®^ easyMag^®^ extraction. No cross-reactivity with other pathogens or the human genome was observed *in-vitro* or *in-silico*. The *in-silico* reactivity analysis showed 100% identity in 98.31% of the available sequences for the MERS screening assay and 97.07% for the confirmatory assay. The remaining sequences only showed minor mismatches and we confirmed the binding capability of our assay by using plasmids containing the mismatches.

**Conclusions:** The fully automated prototype Idylla™ MERS assay requires less than 2 min of hands-on time for sample handling and provides results in less than 90 min without need for experienced staff or extensive training. Due to the integrated sample preparation the handling of the infectious material is reduced to an absolute minimum. The automated sample processing and RT-PCR and data analysis will lead to a sensitive and accurate calling of any MERS-CoV positive sample. The sample-to-result format of the prototype Idylla™ MERS assay offers the possibility for point-of care or centralized laboratory testing.
